Current Licensing
Opportunities
Curated deals available through the BioRich International network. Request details on any opportunity — our team will follow up within 1–2 business days.
HER2-targeted ADC
Novel HER2-targeted antibody-drug conjugate with differentiated linker-payload technology. Phase I dose-escalation complete; favorable tolerability profile demonstrated in first two cohorts.
Oral GLP-1 Receptor Agonist
Once-daily oral GLP-1 receptor agonist in Phase II for type 2 diabetes and obesity. Strong Phase I PK/PD data. Seeking North American commercialization partner.
Enzyme Replacement Therapy
Recombinant enzyme replacement therapy for lysosomal storage disorder. Phase II completed with statistically significant primary endpoint. Regulatory path to NDA/BLA well defined.
IL-17A/F Bispecific Antibody
Bispecific antibody co-targeting IL-17A and IL-17F for moderate-to-severe psoriasis and psoriatic arthritis. Phase I safety and tolerability data available.
4th Generation CAR-T
Next-generation armored CAR-T cell therapy for relapsed/refractory multiple myeloma. Phase I/II enrollment ongoing; early efficacy signals reported.
NLRP3 Inflammasome Inhibitor
Selective NLRP3 inflammasome inhibitor with brain-penetrant properties. In vivo efficacy in Alzheimer's and Parkinson's disease models. Seeking IND-enabling study partner or full licensee.
KRAS G12C Inhibitor
Chinese pharmaceutical company seeking in-licensing rights for an approved or Phase III KRAS G12C inhibitor for the China market. Strong commercial infrastructure; full regulatory support.
PCSK9 Monoclonal Antibody
Established Chinese cardiovascular specialty company seeking in-licensing rights to an approved or late-stage PCSK9 inhibitor. Proven commercial team in tier 1 and tier 2 cities.
KRAS G12V Inhibitor
US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.
US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.
US/EU buyer disease-area mandate for ANCA-associated vasculitis (GPA, MPA, EGPA). Small molecule or biologic; PCC stage or later. Mechanism open.
US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.
US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.
CCR3 Antagonist
US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAG1 Agonist
US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.
ENTPD1 / CD39 Antagonist
US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.
US/EU companies are running an active roadshow to in-license novel, potentially disease-modifying therapies for rare and specialty movement disorders, motor neuron diseases, and rare epilepsies. Open to small and large molecules and siRNA; preclinical-stage assets acceptable and any stage considered. Ex-China / global rights preferred.
TRAIL Agonist
US/EU buyer seeking to in-license TRAIL-agonist programs from PCC through Phase II; indication flexible. Ex-China / global rights preferred.
siRNA / Antisense Oligonucleotide
Well-established US/EU fund seeking siRNA, antisense oligonucleotide, and small-nucleic-acid programs across any disease area; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license cardiovascular and kidney disease programs across modalities (small molecule, large molecule, siRNA, peptide, antisense); preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Polycythemia Vera. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Von Willebrand Disease. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
US/EU buyer seeking to in-license programs for Warm Autoimmune Hemolytic Anemia. Large molecule, small molecule, siRNA, or peptide; preclinical acceptable. Ex-China / global rights preferred.
Energy expenditure / metabolic (non-appetite-suppression)
US/EU buyer seeking to in-license small-molecule weight-loss programs, oral formulations preferred, that drive weight loss by boosting energy metabolism or energy expenditure rather than traditional appetite-suppression mechanisms. Preclinical acceptable. Ex-China / global rights preferred.
CHRM4 Inhibitor
US/EU buyer target-interest mandate for CHRM4 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
COX / 5-LOX Inhibitor
US/EU buyer target-interest mandate for COX / 5-LOX Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
FcRn Inhibitor
US/EU buyer target-interest mandate for FcRn Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
IFN-gamma Inhibitor
US/EU buyer target-interest mandate for IFN-gamma Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAK2 V617F Mutant-Selective Inhibitor
US/EU buyer target-interest mandate for JAK2 V617F Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
LNK Inhibitor
US/EU buyer target-interest mandate for LNK Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
AKT1 Inhibitor
US/EU buyer target-interest mandate for AKT1 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
APJ Antagonist
US/EU buyer target-interest mandate for APJ Antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
BMP9 Recombinant Protein (mimic endogenous BMP9)
US/EU buyer target-interest mandate for BMP9 Recombinant Protein (mimic endogenous BMP9) programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
CALR Mutant-Selective Inhibitor
US/EU buyer target-interest mandate for CALR Mutant-Selective Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Matriptase-2 Inhibitor
US/EU buyer target-interest mandate for Matriptase-2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Plasminogen Inhibitor
US/EU buyer target-interest mandate for Plasminogen Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Protein S Inhibitor
US/EU buyer target-interest mandate for Protein S Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
SF3B1 Splicing Modulator
US/EU buyer target-interest mandate for SF3B1 Splicing Modulator programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
TIE2 Inhibitor
US/EU buyer target-interest mandate for TIE2 Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
TPO Receptor / MPL Inhibitor
US/EU buyer target-interest mandate for TPO Receptor / MPL Inhibitor programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
Oral / Cyclic Peptides
US/EU buyer mandate to in-license oral peptide and cyclic peptide programs. No restriction on development stage or indication. Ex-China / global rights preferred.
Mutant CALR (Calreticulin)
US/EU buyer mandate to in-license programs targeting mutant CALR (calreticulin) for hematologic malignancies. Open to small molecule, biologic, or siRNA modalities; preclinical stage acceptable. Ex-China / global rights preferred.
BBB-Penetrant I&I / CNS Small Molecules
US/EU buyer seeking to in-license blood-brain-barrier (BBB)-penetrant immunology & inflammation (I&I) small molecules, or CNS small molecules for neurodegenerative diseases - particularly assets addressing targets in neuroinflammatory or neurometabolic pathways. Ex-China / global rights preferred.
Cardiovascular - Six Named Indications
Overseas buyer mandate to in-license programs treating cardiovascular disease across six named indications: cardiopulmonary disease, heart failure, atrial fibrillation, stroke, atherosclerosis, and pulmonary hypertension. Preclinical-stage assets acceptable; modality open.
MEK-RAF and KRAS-CYP A (small molecule / molecular glue)
European and American buyer mandate to in-license small-molecule and molecular glue programs targeting MEK-RAF and KRAS-CYP A. Pre-PCC (pre-preclinical-candidate) stage assets are explicitly in scope.
Oral Peptides - Autoimmune & Immune-Related Disease
European and American buyer mandate to in-license oral peptide programs targeting autoimmune and immune-related diseases at near-IND or clinical stage.
First-in-Class Autoimmune Antibodies
European and American buyer mandate to in-license first-in-class (FIC) autoimmune antibody programs at pre-PCC stage. Companion brief to the near-IND oral peptide mandate from the same buyers.
Anti-TRBV9 mAb or TRBV9/CD3 T-Cell Engager
European and American buyer mandate to in-license an IND-stage anti-TRBV9 monoclonal antibody, or a TRBV9/CD3 T-cell engager (TCE). Single-target brief with a firm IND-stage requirement.
TYK2 / JAK / dual TYK2-JAK Inhibitors
European and American buyer mandate to in-license TYK2, JAK, or dual TYK2/JAK small-molecule inhibitors. Preclinical-stage assets acceptable. Expect diligence on JH1 versus JH2 binding and on selectivity across the wider JAK family.
Buyer mandate to in-license programs with potential in inflammation, immunology, and fibrosis. Monoclonal antibodies or small molecules preferred, with a development stage around development candidate (DC) through IND. No target list at present - the buyer is open to reviewing assets across mechanisms.
Molecular Glue / MGD / Non-degrading Glue (e.g. MEK-RAF, KRAS-CYPA)
Buyer mandate for small molecules, molecular glues, and molecular glue degraders. Oral, preferably once daily. Solid tumors preferred; also open to I&I, neurodegeneration, and obesity. Requires FTO complete and composition of matter filed, an established mechanism, clear patient selection, defined PD, and single-agent regression in xenografts. Out of scope: MGDs against IKZF, GSPT1, WEE1, CK1a, CDK (all but CDK4), CCNE1, BTK, ROS1, ALK.
Established MOA in a well-defined population
Companion brief to the molecular glue mandate from the same buyer: any-stage NSCLC or SCLC asset with an established mechanism of action in a well-defined patient population. Clear patient-selection criteria and well-defined PD expected. Worldwide rights preferred, open to carving out Asian markets.
Oral TNF-alpha and TL1A Small-Molecule Inhibitors
European and American buyer mandate to in-license oral small-molecule TNF-alpha and TL1A inhibitor programs. Assets earlier than preclinical candidate (pre-PCC) stage are explicitly in scope.
Rabies Vaccine (non-mRNA)
Buyer mandate to in-license a non-mRNA rabies vaccine, ideally at Phase III or already licensed.
Shingles (Herpes Zoster) Vaccine (non-mRNA)
Buyer mandate to in-license a non-mRNA shingles (herpes zoster) vaccine, ideally at Phase III or already licensed. Companion brief to the non-mRNA rabies vaccine mandate from the same buyer.
In Vivo CAR-T
Buyer mandate to in-license in vivo CAR-T programs in blood cancers. Clinical-phase candidates only.
In Vivo Gene Therapy
Buyer mandate to in-license in vivo gene therapy programs for sickle cell disease (SCD) and beta thalassemia. Clinical-phase candidates only.
In Vivo Gene Therapy
Buyer mandate to in-license in vivo gene therapy programs for Hemophilia A and Hemophilia B. Part of the same in vivo gene therapy brief as the SCD / beta thalassemia and familial hypercholesterolemia mandates.
In Vivo Gene Therapy
Buyer mandate to in-license in vivo gene therapy programs for familial hypercholesterolemia. Part of the same in vivo gene therapy brief as the SCD / beta thalassemia and hemophilia A/B mandates.
Don't see what you're looking for? We have additional opportunities not listed publicly.
Discuss your criteria with our team